Richard Zeifman, Ph.D. is a tenure-track Assistant Professor in the Department of Psychology and Director of the Psychedelic-Assisted Therapy (PATH) Lab at The New School for Social Research. He is also an Adjunct Assistant Professor at the NYU Grossman School of Medicine and an Honorary Lecturer at Imperial College London. Richard completed his Ph.D. in Clinical Psychology at the Toronto Metropolitan University, clinical internship at the Centre for Addiction and Mental Health (CAMH), and postdoctoral fellowship at the NYU Grossman School of Medicine. He is a licensed clinical psychologist in New York.
Richard’s research focuses on examining the safety, efficacy, and mechanisms of change underlying psychedelic therapy. He uses multi-method approaches and serves as a co-investigator on clinical trials of psychedelic therapy for the treatment of psychiatric disorders, including major depressive disorder and posttraumatic stress disorder (PTSD). He has co-authored 46 peer-reviewed publications (including 20 as first or senior author). His research has been supported by $2 million in competitive funding, including $529,000 as principal recipient and $1.5M as co-investigator on federally funded grants.
Richard has experience teaching undergraduate and graduate courses, as well as providing clinical and research supervision for research assistants, graduate students, and psychiatry residents. As a clinician, he provides evidence-based treatments including cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and emotion-focused therapy (EFT), with expertise in treating PTSD, borderline personality disorder, and mood and anxiety disorders. He is a quality-rated Cognitive Processing Therapy (CPT) provider, and serves as a study therapist on clinical trials of psilocybin and MDMA -assisted therapies.